Advertisement
Singapore markets open in 5 hours 22 minutes
  • Straits Times Index

    3,304.00
    +2.22 (+0.07%)
     
  • S&P 500

    5,487.03
    +13.80 (+0.25%)
     
  • Dow

    38,834.86
    +56.76 (+0.15%)
     
  • Nasdaq

    17,862.23
    +5.21 (+0.03%)
     
  • Bitcoin USD

    64,857.98
    +456.99 (+0.71%)
     
  • CMC Crypto 200

    1,381.93
    +44.18 (+3.30%)
     
  • FTSE 100

    8,205.11
    +13.82 (+0.17%)
     
  • Gold

    2,342.70
    -4.20 (-0.18%)
     
  • Crude Oil

    81.47
    -0.10 (-0.12%)
     
  • 10-Yr Bond

    4.2170
    0.0000 (0.00%)
     
  • Nikkei

    38,570.76
    +88.65 (+0.23%)
     
  • Hang Seng

    18,430.39
    +514.84 (+2.87%)
     
  • FTSE Bursa Malaysia

    1,599.79
    -6.34 (-0.39%)
     
  • Jakarta Composite Index

    6,726.92
    -6,734.83 (-50.03%)
     
  • PSE Index

    6,366.03
    -2.77 (-0.04%)
     

AbCellera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024

VANCOUVER, British Columbia, May 28, 2024--(BUSINESS WIRE)--AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the Goldman Sachs 45th Annual Global Healthcare Conference on Monday, June 10, 2024, at 12:20 p.m. Pacific Time (3:20 p.m. Eastern Time).

A live audio webcast of the presentation may be accessed through a link that will be posted on AbCellera's Investor Relations website. A replay will be available through the same link following the presentation.

About AbCellera Biologics Inc.

AbCellera (Nasdaq: ABCL) discovers and develops antibody medicines for indications across therapeutic areas including cancer, metabolic and endocrine conditions, and autoimmune disorders. AbCellera’s engine integrates technology, data science, infrastructure, and interdisciplinary teams to solve the most challenging antibody discovery problems. AbCellera is focused on advancing an internal pipeline of first-in-class and best-in-class programs and collaborating on innovative drug development programs with partners. For more information, please visit www.abcellera.com.

ADVERTISEMENT

View source version on businesswire.com: https://www.businesswire.com/news/home/20240528369330/en/

Contacts

Inquiries
Media: Kathleen Reid; media@abcellera.com, +1(236)521-6774
Business Development: Murray McCutcheon, Ph.D.; bd@abcellera.com, +1(604)559-9005
Investor Relations: Melanie Solomon; ir@abcellera.com, +1(778)729-9116